Weeks after criticising the group’s big pharma partner, John Houston is on his way out.

PD-(L)1 x VEGF bispecifics prove a big draw.

Lynozyfic could have an edge over rival BCMA-targeting bispecifics.

The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.

Any hopes of differentiation could come down to side effects.

Meanwhile, Pfizer reckons it's found the right dose for its KAT6.

The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.

TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.

Conference activity picks up, with the big one – ASCO – at the end of the month.